Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880667 · ClinicalTrials.gov registry record · Phase 1
Adaptive Radiation for Abdominopelvic Metastases
A Phase 1 study of Neoplasm - Soft Tissue Pelvis Malignant Secondary and Malignant Neoplasm of Stomach, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05880667: Recruiting Phase 1 study of Neoplasm - Soft Tissue Pelvis Malignant Secondary and Malignant Neoplasm of Stomach, sponsored by Fox Chase Cancer Center.
NCT05880667 is a Phase 1 study of Neoplasm - Soft Tissue Pelvis Malignant Secondary and Malignant Neoplasm of Stomach that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05880667, a Phase 1 study of Neoplasm - Soft Tissue Pelvis Malignant Secondary and Malignant Neoplasm of Stomach, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Primary Outcome
Cohorts of size 10 will be enrolled, Severe (grade 3) toxicity occurring within 3 months of treatment that is possibly, probably, or definitely related to trial therapy will be assessed.
Conditions Studied
Interventions
- RADIATION Adaptive Stereotactic Body Radiation
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 1 |
What NCT05880667 shows while recruiting
NCT05880667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Neoplasm - Soft Tissue Pelvis Malignant Secondary appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Stereotactic Body Radiation is the first listed.
NCT05880667 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05880667 about?
NCT05880667 is a clinical study titled "Adaptive Radiation for Abdominopelvic Metastases". Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvi...
What is the current status of trial NCT05880667?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-08-01. Estimated completion is 2029-06-01.
What conditions does trial NCT05880667 study?
This clinical trial studies the following conditions: Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach.
What interventions are being tested in trial NCT05880667?
The interventions under investigation include: Adaptive Stereotactic Body Radiation (RADIATION).
Who is sponsoring clinical trial NCT05880667?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05880667 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05880667's enrollment target sits among peer trials
30 1333rd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI